KCM
JAZZ icon

Kennedy Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Kennedy Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.33M Buy
17,603
+375
+2% +$65.5K 0.07% 359
2025
Q4 		$2.93M Sell
17,228
-195
-1% -$29.9K 0.06% 384
2025
Q3 		$2.3M Buy
17,423
+7,056
+68% +$846K 0.05% 428
2025
Q2 		$1.1M Buy
+10,367
New +$1.13M 0.03% 501

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Kennedy Capital Management's JAZZ Position: Q1 2026 in Review

Kennedy Capital Management increased its Jazz Pharmaceuticals (JAZZ) stake by 2.2% in Q1 2026, buying an estimated $65.5K and bringing the position to 17,603 shares worth $3.33M. The position accounts for 0.07% of the portfolio, ranked #359.

Kennedy Capital Management first reported a position in JAZZ in Q2 2025 and has held it in 4 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Kennedy Capital Management held 17,603 shares of Jazz Pharmaceuticals worth $3.33M as of Q1 2026.
  • Kennedy Capital Management bought 375 Jazz Pharmaceuticals shares in Q1 2026, an estimated $65.5K.
  • Jazz Pharmaceuticals made up 0.07% of Kennedy Capital Management's portfolio in Q1 2026, its #359 holding.
  • Kennedy Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Kennedy Capital Management's 13F filing for Q1 2026, filed 13 May 2026.